Kirkland Advises Carlyle-Backed ADICON on Acquisition of Crown Bioscience

"Kirkland & Ellis advised Carlyle-backed ADICON Holdings Limited (HKEX: 9860) on its proposed acquisition of Crown Bioscience from JSR Life Sciences for an enterprise value of US$204 million. Crown Bioscience is a global CRO focused on precision medicine in oncology and immuno-oncology. The transaction was announced on November 13, 2025."

Kirkland & Ellis advised Carlyle-backed ADICON Holdings Limited on its proposed acquisition of Crown Bioscience from JSR Life Sciences. The transaction involves ADICON’s proposed purchase of Crown Bioscience from JSR Life Sciences for an enterprise value of US$204 million. Crown Bioscience is a global contract research organization (CRO) dedicated to advancing precision medicine across oncology, immuno-oncology and other therapeutic areas. ADICON Holdings Limited (HKEX: 9860) is engaged in the provision of independent clinical laboratory services. The transaction was announced on November 13, 2025. Kirkland & Ellis represented ADICON Holdings Limited with a team composed by: corporate lawyers Joey Chau, Brian Ho, Ryan Choi and Gary Chan.

Kirkland Advises Carlyle-Backed ADICON on Acquisition of Crown Bioscience

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads